Overview

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Dacarbazine
Temozolomide
Veliparib